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Abstract
Background: Extensive research has increased our understanding of the molecular alterations needed for non-small
cell lung cancer (NSCLC) development. Deregulation of a pathway including MYCN, HMGA2 and CDKN2A, with the
participation of DICER1, is of importance in several solid tumours, and may also be of significance in the pathogenesis
of NSCLC.
Methods: Gene expression of MYCN, HMGA2, CDKN2A and DICER1 were investigated with RT-qPCR in surgically resected
NSCLC tumour tissue from 175 patients. Expression of the let-7 microRNA family was performed in 78 adenocarcinomas
and 16 matching normal lung tissue samples using microarrays. The protein levels of HMGA2 were determined by
immunohistochemistry in 156 tumour samples and the protein expression was correlated with gene expression.
Associations between clinical data, including time to recurrence, and expression of mRNA, protein and microRNAs
were analysed.
Results: Compared to adenocarcinomas, squamous cell carcinomas had a median 5-fold increase in mRNA expression
of HMGA2 (p = 0.003). A positive correlation (r = 0.513, p < 0.010) between HMGA2 mRNA expression and HMGA2 protein
expression was seen. At the protein level, 90 % of the squamous cell carcinomas expressed high levels of the HMGA2
protein compared to 47 % of the adenocarcinomas (p < 0.0001). MYCN was positively correlated with HMGA2 (p < 0.010)
and DICER1 mRNA expression (p < 0.010), and the expression of the let-7 microRNAs seemed to be correlated with the
genes studied. MYCN expression was associated with time to recurrence in multivariate survival analyses (p = 0.020).
Conclusions: A significant difference in HMGA2 mRNA expression between the histological subtypes of NSCLC was seen
with a higher expression in the squamous cell carcinomas. This was also found at the protein level, and we found
a good correlation between the mRNA and the protein expression of HMGA2. Moreover, the expression of MYCN,
HMGA2, and DICER1 seems to be correlated to each other and the expression of the let7-genes impacted by their
expression. MYCN gene expression seems to be of importance in time to recurrence in this patient cohort with
resected NSCLC.
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Background
The prognosis of lung cancer is dismal. For all stages,
5 year relative survival are 19 % for women and 14 % for
men in Norway [1]. Worldwide, lung cancer is the most
common cause of cancer related death and it is esti-
mated that 1.6 million people die annually due to lung
cancer [2].
Non-small cell lung cancer (NSCLC) constitutes over
80 % of all lung cancers and can be divided into histo-
logical subtypes. Investigation to further unveil the
NSCLC biology includes molecular characterization.
Epidermal growth factor receptor (EGFR) mutational
testing has been performed routinely in Norway since
2010. Targeted therapies such as EGFR inhibitors and
anaplastic lymphoma kinase (ALK) inhibitors are cur-
rently in clinical use. Increased understanding of differ-
ent levels of tumour development, of genetic, epigenetic,
protein alterations and their functional influence are of
clinical importance. For a disease where a majority of
patients are diagnosed in late stages, there is a need to
discover biomarkers as well as new targets for thera-
peutic interventions.
Overexpression of the HMGA2 gene is linked to the
development of cancer [3]. The HMGA2 gene encodes a
non-histone chromatin modifying protein that binds to
AT-rich regions in the DNA; thus leading to a change in
DNA structure and interaction with transcription factors
influencing cell growth, proliferation, differentiation and
cell death [4]. HMGA proteins are abundantly expressed
during fetal development, but scarcely present or even
absent in normal adult tissue [5]. In NSCLC, however,
re-expression of HMGA2 is proposed as a common
event and considered as a molecular marker [6]. Indeed,
HMGA2 protein expression is in some studies shown re-
lated to lung cancer development and progression, and
inversely associated with lung cancer survival [7, 8].
The MYC oncogenes are well characterized partici-
pants in cell proliferation, growth, differentiation and
apoptosis [9]. One of the MYC family members, MYCN,
functions as a positive regulator of LIN28B, a known re-
pressor of the let-7 family of microRNAs [10, 11]. Micro-
RNAs are small non-coding RNAs that regulate gene
expression, making them important players in cancer de-
velopment and progression [12]. LIN28 protein binds to
pre-let-7 s and prevents further processing into mature
let-7 microRNAs by DICER1 [13]. HMGA2 is a thor-
oughly described target of let-7 s and a loss of let-7 micro-
RNAs can lead to HMGA2 overexpression, shown both in
cell lines and in solid tumours [14, 15]. Furthermore,
through downregulation of the tumour suppressor gene
CDKN2A, HMGA2 is shown to be involved in stem cell
renewal [16]. CDKN2A level is previously demonstrated
as an independent prognostic factor in non-small cell lung
carcinoma [17].
The role of a deregulated pathway including MYCN,
HMGA2 and CDKN2A with the participation of DICER1
(Fig. 1) has not previously been investigated in NSCLC. In
Fig. 1 The MYCN, HMGA2, CDKN2A pathway. MYCN functions as a
positive regulator of LIN28B, a known repressor of the let-7 family of
microRNAs via binding to DICER1. Loss of let-7 microRNAs can lead to
HMGA2 overexpression that may result in a downregulation of CDKN2A
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this study we explore the significance of MYCN,
HMGA2, CDKN2A and DICER1 in NSCLC tumours by
gene expression analysis. HMGA2 protein expression
data are evaluated as well as microarray information
on let-7 microRNAs, to elucidate possible correlations.
Differences in histological or clinical subgroups are
assessed. Finally, associations with time to recurrence
are examined.
Methods
Patient cohort
Eligibility criteria for the present study were patients
diagnosed with lung cancer stage I-IIIa, treated with cu-
ratively intended surgery at Oslo University Hospital –
Rikshospitalet, from 2006 to 2010.
Clinical data were collected from the hospital’s medical
records. Follow up data procured via questionnaires ad-
ministered to the patients, through copies of medical re-
cords from local hospitals and information from general
practitioners. All data were registered in a project data-
base. The patients were followed until death or 5 years
past surgery. Tumours were staged according to the
Union for International Cancer Control (UICC), TNM 7,
and histopathological parameters were retrieved from
the pathology reports. Tumours were grouped in three
based on histology; adenocarcinomas, squamous cell car-
cinomas and others (including large cell carcinomas, un-
differentiated carcinomas, adeno-squamous carcinomas,
small cell carcinomas and carcinoids). Neoadjuvant and
adjuvant treatment were given according to guidelines
based on TNM stage and the patient’s age.
Tumour samples
The tumour specimens were collected by thoracic sur-
geons during lung cancer surgery. They were snap-frozen
in liquid nitrogen and stored at − 80 °C until further
processing.
RNA isolation
Total RNA was extracted from the tumour specimens
using standard TRIZOL methods (Invitrogen, Carlsbad,
CA). RNA quantity and quality were assessed by Nano-
Drop ND-1000 spectrometer (NanoDrop technologies)
and by RNA integrity numbers (RIN) measured using
the 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA).
Reverse transcription quantitative polymerase chain
reaction (RT-qPCR) for gene expression
Gene expression of the four selected genes; MYCN,
HMGA2, CDKN2A and DICER1 was measured on tumour
samples by RT-qPCR using the Applied Biosystems
7900HT Fast Real-Time PCR system (7900HT Fast System,
Applied Biosystems, Foster City, CA). Single stranded
cDNA was synthesized from totalRNA in samples using
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Human ACTB (beta actin) was used as
endogenous control and a commercial Ambion breast con-
trol (Life Technologies) used as a calibrator in the qPCR.
ACTB where chosen as a single endogenous control when
the RT-qPCR where performed in 2011–2012 based on
earlier satisfactory experience at our institution, and the
current perception of endogenous controls in RT-qPCR
experiments in general. All reactions were performed as
triplicates for each sample. Outliers were omitted from fur-
ther analysis. Negative and positive controls were included
in every run.
The mRNA expression values was quantified as ΔΔCt
values, where Ct = threshold cycle, ΔCt = (Ct target
mRNA - Ct B-actin) and ΔΔCt = (ΔCt target mRNA - ΔCt
calibrator). Relative quantification (fold change) of mRNA
expression was calculated by the 2 –ΔΔCt method [18]
using the RQ manager software, version 1.2 (Applied
Biosystems).
In a total of 175 patients included, gene expression data
was generated from 170 tumour samples for MYCN, 132
tumour samples for HMGA2, 171 tumour samples for
CDKN2A and 164 tumour samples for DICER1, respect-
ively. A REMARK diagram of the patients is presented in
Additional file 1: Figure S1.
Additional RT-qPCR analyses did not pass the quality
control or were not possible to perform due to lack of
sufficient tumour material.
Immunohistochemistry
HMGA2 protein expression levels in the tumour tissue
were determined by immunohistochemistry. We used
rabbit anti-HMGA2 antibodies (www.biocheckinc.com)
and Dako EnVision Flex + System (K8012) on tissue mi-
cro arrays (TMAs) from 156 tumour samples. All sam-
ples were represented on the TMAs in duplicates.
Protein expression was scored by counting nuclear stain-
ing positivity; either as negative (0), less than 10 % tumour
cells with strong nuclear staining (1+), 10–50 % tumour
cells with strong nuclear staining (2+) or more than 50 %
tumour cells with strong nuclear staining (3+). Samples
with score 2+ and 3+ were considered overexpressing the
HMGA2 protein.
MicroRNA expression
For microRNA profiling, microRNA microarrays from
Agilent Technologies (Agilent human microRNA micro-
array kit release 16.0, 8 x 60 K) was used in 78 tumour
tissue samples. For 16 of the cases matching normal
lung tissue was also available for analysis. The normal
lung tissue was collected from the lung or lobe removed
during the operation, at least 10 cm apart from the
macroscopic tumour. The microRNA kit encodes 1205
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human microRNAs and 144 human viral microRNAs
listed in the Sanger miRBase (release 16.0). Arrays were
scanned with Agilent Microarray Scanner (Agilent Tech-
nologies, Santa Clara, CA) and raw data pre-processed
with Agilent Feature Extraction Software (v. 10.7.3.1),
with default parameters employed. MicroRNAs detected
in less than 10 % of the samples were filtered out, 570
microRNAs, including 10 microRNAs of the let-7family,
remained for further analysis. Microarray data were
processed by log2 transformation, and normalized be-
tween arrays by the 90th percentile method using the
Genespring GX analysis Software v.12.1 (Agilent Tech-
nology). Some of the results on the microRNA profiling
have previously been published by Bjaanæs et al. [19]
and characteristics of the patients are presented in
Additional file 1: Table S1.
Validation
For validation of the survival analyses, two data sets
were used. The first set contained data from mainly
adenocarcinomas from our own research group, while
the other was composed of data from squamous cell car-
cinomas obtained via the The Cancer Genome Atlas
(TCGA) data portal [20].
We used the SurePrint G3 Human Gene Expression
8x60K Microarray Kit (Agilent Technologies) for mRNA
profiling in 187 lung cancer samples, including 184 lung
adenocarcinomas. The arrays were scanned with Agilent C
scanner (Agilent’s Scan control software, version A.8.4.1)
and the dataset extracted with the Agilent Feature Extrac-
tion Software. In GeneSpring GX 12 (Agilent Technolo-
gies) the data was normalized by using the 75 percentile
method. Median follow up for patients still alive in this
cohort who had not developed metastasis or a local recur-
rence was 49 months (range 26–60 months). Forty percent
of the patients in this cohort had a recurrence of lung can-
cer disease during the follow-up time.
A dataset of lung squamous cell carcinoma was ob-
tained through the TCGA data portal where mRNA ex-
pression data were available in a total of 508 tumour
specimens defined as lung squamous cell carcinoma.
Clinical data and details of progression and survival
were, however, only available for a total of 280 of the
patients on the website, and these patients were thus
included in the survival analysis. Median follow up time
in the TCGA dataset for patients still alive with no me-
tastasis or local recurrence was 20 months, ranging
from 2 to 60 months and 27 % of the patients experi-
enced local recurrence or distant metastasis during
follow-up.
Clinical details for both datasets are available in Add-
itional file 1: Table S2 and Additional file 1: Table S3.
Statistical analyses
Data are reported using descriptive statistics with percent-
ages, means, standard deviations, medians and ranges.
Relative quantification of mRNA expression (fold
change) of the selected genes; MYCN, HMGA2, CDKN2A
and DICER1 in the tumour samples was analysed in differ-
ent clinical subsets such as histology, stage, sex and smok-
ing history. Differences in median values between groups
regarding continuous mRNA expression data were ana-
lysed using non-parametric tests, Mann–Whitney U
test and/or Kruskal Wallis test where appropriate. Fold
change values are not normally distributed and analyses
of correlations were done with Spearman’s Rank Order
correlation. Expression of HMGA2 protein in different
histological entities, were analyzed by Chi-square test.
To evaluate differences in mean let-7 microRNA
expression in tumour and normal lung tissue, and to
see whether mRNA expression were associated with
mean microRNA let-7 data, independent t-tests were
performed.
For the survival analyses, follow up data existed for
all included patients. Time to recurrence of lung cancer
was calculated as the interval between the date of oper-
ation and date of local relapse, distant metastases, or
death due to lung cancer. Patients that died of other
causes without local relapse or metastases were cen-
sored in the survival analyses (n = 38). One of the par-
ticipants died 13 days after the operation in cardiac arrest,
and was excluded from the survival analyses. Of the
remaining 37 patients that died of alternative causes it was
verified through medical records that 15 patients died
from cardiovascular disease. 15 patients died from other
verified diseases such as COPD, pneumonia and septicae-
mia. For 8 patients no definitive cause of death were un-
covered, however neither of these patients had a verified
relapse of NSCLC prior to death, nor were there any indi-
cation of a lung cancer related death in the medical re-
cords procured.
Survival curves and estimation of statistical signifi-
cance between groups were performed using the
Kaplan-Meier method and log rank test, respectively;
here mRNA expression (fold change) was categorized
into high and low values based on the median gene ex-
pression value. Factors associated with lung cancer
progression were analyzed using the Cox proportional
hazard regression model also using dichotomous fold
change data for gene expression. Although not signifi-
cant in the log rank tests performed, age at surgery,
sex, stage and histology, were still included in the
multivariate Cox regression analysis, due to high clin-
ical relevance.
A p-value ≤ 0.050 was considered statistically signifi-
cant. All statistical analyses were performed using SPSS
version 21.0 (SPSS Inc., Chicago, MO, USA).
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Ethical considerations
This project was approved by the regional ethics committee
(Regional comittees for medical and health research ethics -
South East) (Approval no:S-06402b) and the institutional
review board (Protokollutvalget, Radiumhospitalet). The
patients were given oral and written information prior to
inclusion. A written consent was obtained from all the
participants.
Results
Patient characteristics
One hundred and seventy-five patients were included in
the study. The median age at surgery was 66 years
(range 34 to 82 years) and 54 % were male. The tumour
samples included 57 % adenocarcinomas, 25 % squa-
mous cell carcinomas and 18 % others. According to the
current TNM classification, 55 % of the patients were in
pTNM stage I, 31 % in stage II and 13 % in stage IIIa. Fifty
four of the patients (31 %) received adjuvant chemother-
apy, 3 patients received neoadjuvant chemotherapy and 9
patients received radiotherapy (adjuvant or neoadjuvant).
During follow up, 60 participants (34 %) presented with
relapse of disease; either as a local recurrence or meta-
static disease. At the end of follow up 86 patients (49 %)
had died. For those whose disease recurred, the median
time from initial surgery to diagnosis of relapse was
18 months (range 2 to 60 months). Clinical and patho-
logical features and outcome parameters are summarized
in Table 1.
Gene expression
We discovered a significant difference in the median
values of HMGA2 mRNA expression according to tumour
histology (p = 0.003) with a considerably higher median
fold change value in the squamous cell carcinoma group
(70.6 fold) compared to adenocarcinomas (13.1 fold) and
others (5.8 fold) (Table 2). Regarding CDKN2A expression,
a significantly higher median expression was found in
women compared to men (p = 0.013). Boxplots illustrating
the distribution of gene expression is presented in
Additional file 1: Figure S2.
HMGA2 protein expression
In total, 86 (55 %) of the tumour samples were scored with
a high expression level of the HMGA2 protein. In histo-
logical subsets, 90 % of the squamous cell carcinomas
expressed high levels of HMGA2, while 47 % of the adeno-
carcinomas showed high expression of the protein; this
Table 1 Characteristics of the patient cohort
Age at surgery (y):
Median/range: 66/34–82
n = 175 %
Sex:
Male: 95 54.3
Female: 80 45.7
Smoking history:
Current: 107 61.1
Former: 57 32.6
Never: 11 6.3
Weight loss:
No weight loss: 48 27.4
Weight loss < 10 % 99 56.6
Weight loss ≥ 10 % 22 12.6
No data: 6 3.4
Tumor size:
< 3 cm 99 56.6
> 3 cm - ≤5 cm 55 31.4
> 5 cm- ≤7 cm 19 10.9
> 7 cm 2 1.1
Stage:
I: 97 55.4
II: 55 31.4
IIIa: 23 13.1
Histology:
Adenocarcinoma: 99 56.6
Squamous cell carcinoma: 44 25.1
Other: 32 18.3
EGFR:
EGFR mutated: 13 7.4
EGFR not mutated: 159 90.9
EGFR not tested: 3 1.7
Chemotherapy:
Adjuvant chemotherapy: 54 30.9
Neoadjuvant chemotherapy: 3 1.7
No chemotherapy: 116 66.3
No data: 2 1.1
Radiotherapy:
Adjuvant or neoadjuvant: 9 5.1
No radiotherapy 166 94.9
Status at 5 year follow up:
Alive with no disease: 81 46.3
Alive with disease: 8 4.6
Dead: 86 49.1
Cause of death (n = 86):
Table 1 Characteristics of the patient cohort (Continued)
Lung cancer: 48 55.8
Cardiovascular disease: 15 17.4
Other: 23 26.7
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Table 2 Relative quantification of mRNA expression (fold change) in tumour sample subsets stratified by histology, stage, sex and smoking history
Genes All Histology Stage Sex Smoking history
AC SCC Other p-value I II III p-value Male Female p-value Never Former Current p-value
MYCN n = 170 n = 94 n = 44 n = 32 n = 94 n = 54 n = 22 n = 91 n = 79 n = 11 n = 54 n = 105
median 0.43 0.46 0.54 0.24 0.517 0.46 0.38 0.40 0.723 0.47 0.37 0.057 1.12 0.47 0.37 0.195
(range) (0.01–
943.85)
(0.03–
943.85)
(0.02–
10.25)
(0.01–
43.00)
(0.02–
88.53)
(0.01–
166.37)
(0.32–
943.85)
(0.01–
943.85)
(0.03–
166.37)
(0.20–
13.55)
(0.01–
88.53)
(0.03–
943.85)
HMGA2 n = 132 n = 71 n = 36 n = 25 n = 70 n = 41 n = 21 n = 79 n = 53 n = 8 n = 44 n = 80
median 20.01 13.12 70.65 5.77 0.003** 15.33 40.88 7.58 0.360 17.33 23.16 0.758 18.28 29.14 16.98 0.945
(range) (0.21–
33877.07)
(0.56–
2736.65)
(0.71–
33877.07)
(0.21–
10749.96)
(0.21–
13499.32)
(0.27–
33877.07)
(0.31–
2168.39)
(0.27–
33877.07)
(0.21–
13499.32)
(2.67–
640.82)
(0.21–
13499.33)
(0.31–
33877.07)
CDKN2A n = 171 n = 96 n = 44 n = 31 n = 95 n = 53 n = 23 n = 93 n = 78 n = 10 n = 55 n = 106
median 4.94 4.93 4.85 6.55 0.777 4.93 5.18 5.48 0.811 3.77 8.40 0.013*,** 5.25 4.48 5.31 0.505
(range) (0.07–
7818.30)
(0.08–
7818.30)
(0.21–
333.40)
(0.07–
193.94)
(0.07–
7818.30)
(0.08–
193.94)
(0.19–
156.38)
(0.07–
193.94)
(0.43–
7818.30)
(2.17–
179.05)
(0.07–
7818.30)
(0.08–
333.40)
DICER1 n = 164 n = 93 n = 40 n = 31 n = 87 n = 54 n = 23 n = 89 n = 75 n = 11 n = 51 n = 102
median 0.99 0.91 1.00 1.25 0.304 1.03 0.90 0.88 0.550 1.01 0.87 0.763 1.68 0.95 0.89 0.698
(range) (0.21–
119.51)
(0.24–
119.51)
(0.21–7.76) (0.25–5.07) (0.21–
45.80)
(0.25–
119.51)
(0.27–
5.70)
(0.21–7.76) (0.24–
119.51)
(0.27–
2.23)
(0.21–
45.80)
(0.25–
119.51)
AC adenocarcinoma, SCC squamous cell carcinoma, *p-value < 0.05 Mann–Whitney U test. **p-value < 0.05 Kruskal-Wallis test
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difference was highly significant (p < 0.0001). It is worth
noting that none of the 8 carcinoid tumours expressed
HMGA2 protein. Protein expression levels according to
histological subtypes are presented in Table 3. Microscopy
images of HMGA2 protein in NSCLC are shown in Fig. 2.
Correlations, mRNA expression and protein
A positive correlation coefficient of 0.513 was identified
between HMGA2 mRNA expression and HMGA2 pro-
tein expression (p < 0.010). MYCN and HMGA2 mRNA
expression showed a positive, albeit weaker correlation
(correlation coefficient of 0.232, p < 0.010). DICER1
mRNA expression was positively correlated to MYCN,
HMGA2 and CDKN2A mRNA expression with correlation
coefficients of 0.463 (p < 0.010), 0.174 (p < 0.050) and 0.167
(p < 0.050) respectively (Additional file 1: Figure S3).
A significant correlation between HMGA2 and CDKN2A
mRNA was not seen. The correlation coefficient of
CDKN2A mRNA expression and HMGA2 protein was
weakly negative, however not significant.
Let-7 microRNAs
All of the measured let-7 s had a mean expression
level significantly lower in tumour tissue compared to
normal lung tissue. Compared to tumours with low
HMGA2 mRNA expression, mean expression of let-
7a, let-7c, let-7d and let-7f was significantly lower in
tumours with high expression of HMGA2 whereas let-
7d was higher. Mean expression of let-7a and let-7d
was significantly different depending on mRNA ex-
pression in all of the four genes in question, while
mean let-7f was significantly different in MYCN,
HMGA2 and CKDN2A (Table 4). Details on the inde-
pendent t-tests performed are included in supplemen-
tary tables (Additional file 1: Table S4, Additional file 1:
Table S5, Additional file 1: Table S6, Additional file 1:
Table S7, Additional file 1: Table S8).
Survival analyses
In survival analyses patients with a MYCN mRNA ex-
pression level above median had a significantly worse
prognosis compared to patients with MYCN mRNA ex-
pression level below median, both in the cohort as a
whole (log rank test, p = 0.029) and in patients with
squamous cell carcinomas (log rank test, p = 0.044)
(Fig. 3). In the multivariate Cox regression analysis
adjusting for age, gender, stage and histology, the associ-
ation between MYCN and time to recurrence was con-
firmed (p = 0.020) (Table 5). These findings were not,
however, validated in a squamous cell carcinoma cohort
with clinical follow-up data from the TCGA project or
in the cohort with mRNA data from adenocarcinomas.
In tumours with apparent co-regulation of expression
of HMGA2 and MYCN, there was a significantly better
outcome when both genes were downregulated com-
pared to the alternatives (log rank test, p = 0.040)
(Fig. 3).
Among patients with stage I disease, low HMGA2
protein expression was associated with better progno-
sis compared to the patients with overexpression of
the protein (log rank test, p = 0.034) (Additional file 1:
Figure S4). Patients with large cell carcinomas and low
expression of the HMGA2 protein also had a better
outcome (log rank test, p = 0.014). There was no sig-
nificant relationship between HMGA2 protein expres-
sion and progression free survival among all patients
Table 3 Levels of HMGA2 protein in histological subsets of
non-small cell lung cancer
Total Low expression
of HMGA2
Overexpression
of HMGA2
Adenocarcinoma 88 47 41
Squamous cell carcinoma 38 4 34
Others 30 19 11
Total 156 70 86
Fig. 2 Expression of HMGA2 protein in NSCLC. Photomicrographs of NSCLC specimens stained with anti-HMGA2 antibodies. a represents a squamous
cell carcinoma sample demonstrating strong immunoreactivity whereas negative staining is shown in b, an adenocarcinoma sample
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included as a whole. Moreover, the mRNA levels of
CDKN2A or DICER did not influence the prognosis in
the different histological subgroups.
Discussion
The development of NSCLC includes multiple genetic
and epigenetic alterations that may lead to activation of
pathways promoting tumour growth as well as inhibition
of pathways of tumour suppression. NSCLC has among
the greatest number of genetic aberrations of all malig-
nant tumours [21]. This is the first study investigating
the pathway involving genes MYCN, HMGA2, CDKN2A,
DICER1 and the let-7 family of microRNAs in NSCLC,
while several findings have indicated a connected path-
way involving these players [14–17].
The HMGA2 protein plays an important role in
growth during embryonic development. It is mainly
expressed in embryos, and mutant mice with HMGA2
deficiency develop a pygmy phenotype [22]. Close to ab-
sent in adult tissue, re-expression in tumours has led to
investigations of causality. It is previously known that
HMGA2 chromosomal rearrangements are implicated in
benign tumours of mesenchymal origin [23] and overex-
pression of the HMGA2 protein is found in a variety of
malignant tumour types such as breast cancer [24], pan-
creatic cancer [25], oral squamous cell carcinomas [26]
as well as NSCLC [6–8]. In our study, analysis of fresh-
frozen NSCLC tumour tissue by RT-qPCR revealed a
significant difference in HMGA2 mRNA expression in
histological subsets; with an elevated median expression
value in the squamous cell carcinomas of approximately
5-fold over the median value of adenocarcinomas. A
similar pattern was seen for HMGA2 protein; with a sig-
nificant distinction of nuclear staining in the different
histological groups. Close to all squamous cell carcinomas
expressed high levels of HMGA2 compared to 46 % of the
adenocarcinomas, and this difference was highly signifi-
cant. Moreover, a strong positive correlation was demon-
strated between HMGA2 mRNA and HMGA2 protein
expression. Previous studies have indicated a role for thy-
roid transcription factor-1 (TTF-1) in the regulation of
HMGA2 expression, as a loss of TTF-1 triggers overex-
pression of HMGA2 [27]. Indeed, squamous cell carcin-
omas are usually negative for TTF-1, while the opposite is
shown in adenocarcinomas [28].
An increase in HMGA2 expression (RT-qPCR) in
tumour matching non-tumour tissue, with a significant
higher increase in squamous cell carcinoma compared to
Table 4 Mean let-7 microRNA expression associated with mRNA
expression in tumour samples
MYCN HMGA2 CDKN2A DICER1
Let-7a 0.044* 0.019* 0.025* 0.036*
Let-7a* 0.362a 0.207 0.720 0.265a
Let-7b 0.313 0.055 0.763 0.028*
Let-7c 0.729 0.021* 0.167 0.197
Let-7d 0.022* 0.038* 0.041* 0.040*
Let-7d* 0.107 0.301 0.040* 0.552
Let-7e 0.104 0.073 0.002* 0.102
Let-7f 0.048* 0.023* 0.019*, a 0.081
Let-7 g 0.012* 0.013*, a 0.030* 0.037*
Let-7i 0.166 0.105 0.097a 0.006*
Associations presented with p-values only. *p-value < 0.05, calculated by
independent samples t-test. aequal variance not assumed (Levene’s F test)
Fig. 3 Associations between gene expression and patient outcome. mRNA fold change values dichotomized to high (green) or low (blue) expression
based on the median expression level. High expression of MYCN mRNA had a significantly worse prognosis compared to lower expression levels in all
tumour samples (a, p = 0.029) and in a subset of squamous cell carcinomas (b, p = 0.044). Lower expression of both MYCN and HMGA2 (co-expressed)
had a significantly better prognosis compared to the other alternatives (c, p = 0.040)
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Table 5 Predictors for Progression Free Survival (n = 174)
Variable Univariate Cox model Multivariate Cox model
HR 95 % CI p-value HR 95 % CI p-value
Age at surgery 1.01 0.98–1.04 0.713 1.01 0.98–1.04 0.428
Sex
Male Reference Reference
Female 1.38 0.83–2.3 0.218 1.46 0.85–2.51 0.170
Stage
Stage I Reference Reference
Stage II + III 1.36 0.82–2.26 0.234 1.26 0.75–2.12 0.389
Histology
Adenocarcinoma Reference Reference
Squamous cell carcinoma 0.94 0.50–1.78 0.850 1.06 0.55–2.07 0.856
Other 1.08 0.56–2.09 0.814 1.30 0.65–2.59 0.458
Chemotherapy
Chemotherapy Reference
No chemotherapy 1.26 0.72–2.18 0.421
Smoking status
Current Reference
Former 1.22 0.71–2.09 0.478
Never 1.33 0.52–3.40 0.557
Tumor size
≤ 3 cm Reference
> 3 cm - ≤ 5 cm 1.67 0.97–2.89 0.064
> 5 cm 1.13 0.50–2.57 0.776
EGFR status
EGFR not mutated Reference
EGFR mutated 0.93 0.37–2.33 0.876
Weight loss
No weight loss Reference
< 10 % 1.28 0.70–2.39 0.422
≥ 10 % 1.70 0.74–3.93 0.214
MYCN
<median expression Reference
>median expression 1.78 1.05–3.02 0.032* 1.90 1.11–3.26 0.020*
HMGA2
<median expression Reference
>median expression 1.18 0.66–2.11 0.588
CDKN2A
<median expression Reference
>median expression 1.37 0.81–2.29 0.239
DICER1
<median expression Reference
>median expression 1.02 0.61–1.72 0.943
mRNA expression data represented in the analysis as dichotomous variables (fold change). *p-value < 0.05
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adenocarcinoma, was previously reported by Meyer et al.
[6]. These results are consistent with our findings. Many
studies highlight the role of HMGA2 protein in cancer
progression, HMGA2 protein levels in primary lung tu-
mours has been shown to correlate with increasing
tumour grade and has furthermore been regarded as a ne-
cessity for a transformed phenotype in metastatic NSCLC
cell lines [7]. Accordingly, HMGA2 protein expression
was entirely devoid in the slow growing carcinoids in our
study and HMGA2 protein levels in stage I patients were
associated with progression free survival supporting the
role of HMGA2 as a marker of aggressiveness.
We identified a positive correlation between MYCN and
HMGA2 mRNA. In addition, DICER1 expression was
positively correlated to MYCN, HMGA2 and CDKN2A,
supporting the notion of the involvement of this pathway.
When focusing on the tumours with seemingly co-
regulated HMGA2 andMYCN expression, we found a sig-
nificantly better outcome when both genes were downreg-
ulated compared to the remainders (Fig. 3). This also
supports the involvement of this pathway in lung carcin-
omas, and has not been demonstrated previously. How-
ever, it is known in general that the genes investigated are
also regulated by several other factors and that the contri-
bution of HMGA2, in particular, is complex, involving
several other genes and proteins [4].
Let-7 microRNA expression is scarce in embryonic
stages, but increases in tissue following mature differen-
tiation and is suggested as putative tumor suppressors
[29]. As confirmed by our study, normal lung tissue
showed a higher level of let-7 expression compared to
adenocarcinoma tumor samples. Moreover, HMGA2 is a
well characterized target of the let-7 microRNA family
and known to be inversely correlated with HMGA2 ex-
pression in NSCLC cells [30, 31]. We found several let-7
microRNAs to be differentially expressed comparing
high and low HMGA2 gene expression; let-7a, let-7c and
let-7f was seen inversely correlated, consistent with the
biological presumption that loss of let-7 inhibition leads
to HMGA2 overexpression in cancer. It has also been
shown that aberrant expression of let-7 is more common
in squamous cell carcinoma compared to adenocarcin-
omas [32]. Our cohort included only a few squamous
cell carcinoma samples, but we still received a similar
end result.
Although we identified a significant impact of MYCN-
expression levels on progression free survival in both the
cohort investigated as a whole, and in the squamous cell
carcinomas alone, this was not validated in the TCGA
data. There may be several explanations for this lack of
validation. The TCGA project was initiated for molecu-
lar analyses, and the clinical data was missing in many
of the available cases. Moreover, a fairly large proportion
of patients with existing clinical data had only a short term
follow-up. Our cohort in the present study consisted of
several histological subgroups, and each subgroup had
limited number of cases. We propose that similar survival
analyses need to be further investigated in larger cohorts
of homogenous subtypes in future studies.
The mRNA level of HMGA2, CDKN2A and DICER1
did not influence survival in our study significantly. Pre-
vious studies have not investigated this fully in specific
histological lung cancer subgroups, but have shown that
the HMGA2 protein is involved in the transformation of
lung cancer cells. Its role might therefore very well be in
the initiation and establishment of the cancer. In neuro-
blastoma, MYCN, LIN28B and let-7 seem to be involved
and MYCN amplification is correlated with adverse clin-
ical outcome [33, 34]. This is a more benign disease
although the location of tumours may unfavourably im-
pact the prognosis.
One of the limitations to this study is the low number
of samples in our subgroup analyses. In addition, cohorts
with solid clinical data and follow up would ensure fur-
ther investigations of the prognostic impact activation of
this pathway in lung cancers, and in the different histo-
logical subtypes.
Conclusion
In this study we have identified a significant difference be-
tween the histological subtypes of NSCLC and HMGA2
expression at both the mRNA and protein level. The more
benign histology of carcinoids lacked HMGA2 expression,
while among squamous cell carcinomas, most samples
showed high expression. We have also demonstrated a
correlation between mRNA expression of HMGA2 and
HMGA2 protein expression. The mRNA expression levels
of MYCN and HMGA2 and DICER1 were significantly
correlated, and co-regulation of expression of HMGA2
and MYCN, had a significant impact on survival. The im-
pact on survival is probably complex, and needs to be in-
vestigated in larger cohorts of specific histological non-
small cell lung cancer subgroups.
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